Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
The investment will accelerate the overall Sarclisa development program
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Subscribe To Our Newsletter & Stay Updated
